MedPath

AuraClens™ System in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast

Not Applicable
Active, not recruiting
Conditions
Breast Fat Grafting Retention
Interventions
Device: AuraGen 1-2-3 with AuraClens
Registration Number
NCT05258305
Lead Sponsor
Sientra, Inc.
Brief Summary

Prospective, multi-center, non-randomized, open-label, post-market clinical study evaluating adipose graft retention over time from lipoaspirate processed using the AuraGen 1-2-3™ with AuraClens™ Lipoaspirate Wash System.

Detailed Description

Autologous fat transfer (AFT) is a medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen1-2-3 with AuraClens Lipoaspirate Wash System is designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister. The study population will consist of up to 200 subjects in (2) cohorts: 100 subjects undergoing breast reconstruction and 100 subjects undergoing breast augmentation. All subjects will receive autologous lipoaspirate processed with the A123+ AuraClens and will be followed post-procedure at 1-, 3-, 6-, and 12-months. Fat graft retention will be evaluated with 3D imaging using the Canfield Vectra XT imaging system. Patient satisfaction will be measured between baseline and the post-procedure follow-up visits using a breast satisfaction questionnaire.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Female patients > 22 years and < 65 years of age.
  • Patients with a BMI < 35.
  • Patients undergoing an aesthetic fat grafting procedure to the breast (breast augmentation) with or without a breast implant.
  • Patients must be able to provide written informed consent, understand and be willing to comply with study-related procedures and follow-up visits.
  • Patients must be non-smokers.
  • Patients with available/adequate harvest sites for fat grafting.
  • Anticipated harvested fat volume between 200 and 700 cc.
  • Anticipated fat injection volume between 50 and 350 cc per breast.
  • Anticipated breast implant volume between 200 and 550 cc.
  • Patients must agree to maintain their weight (i.e., within 5%) by not making any major changes in diet or lifestyle during the study.
Exclusion Criteria
  • Skin rash in the treatment area.
  • Patients who smoke or use nicotine products.
  • Patients with bleeding disorders or currently taking anticoagulants.
  • Patients with history of trauma or surgery to the treatment area.
  • Patients with history of breast cancer.
  • Active, chronic, or recurrent infection.
  • Compromised immune system.
  • Hypersensitivity to analgesic agents.
  • Co-morbid condition that could limit ability to participate in the study or to comply with follow-up requirements.
  • Untreated drug and/or alcohol abuse.
  • Pregnant or breastfeeding.
  • Any issue that, at the discretion of the Investigator, would contra-indicate the patient's participation.
  • Patients who do not wish to have the study area (breast) photographed.

Reconstruction Subjects

Inclusion Criteria:

  • Female patients > 18 years and < 65 years of age.
  • Patients with a BMI < 35.
  • Patients undergoing a fat grafting procedure to the breast in a second or third stage of a staged breast reconstruction, with or without a breast implant.
  • Patient is at least 1 year post-completion of chemotherapy.
  • Patients must be able to provide written informed consent, understand and be willing to comply with study-related procedures and follow-up visits.
  • Patients must be non-smokers.
  • Patients with available/adequate harvest sites for fat grafting.
  • Anticipated harvested fat volume between 200 and 700 cc.
  • Anticipated fat injection volume between 50 nd 350cc per breast.
  • Anticipated breast implant volume (if applicable) between 200 and 550 cc.
  • Patients must agree to maintain their weight (i.e., within 5%) by not making any major changes in diet or lifestyle during the study.

Exclusion Criteria:

  • Skin rash in the treatment area.
  • Patients who smoke or use nicotine products.
  • Patients with bleeding disorders or currently taking anticoagulants.
  • Patients undergoing active treatment for breast cancer.
  • Active, chronic, or recurrent infection.
  • Compromised immune system.
  • Hypersensitivity to analgesic agents.
  • Co-morbid condition that could limit ability to participate in the study or to comply with follow-up requirements.
  • Untreated drug and/or alcohol abuse.
  • Pregnant or breastfeeding.
  • Any issue that, at the discretion of the Investigator, would contra-indicate the patient's participation.
  • Patients who do not wish to have the study area (breast) photographed.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ReconstructionAuraGen 1-2-3 with AuraClensSubjects undergoing reconstructive fat grafting procedure to the breast with or without a breast implant.
AugmentationAuraGen 1-2-3 with AuraClensSubjects undergoing an aesthetic fat grafting procedure to the breast with or without a breast implant.
Primary Outcome Measures
NameTimeMethod
Fat Grafting Volume Retention1 Year

Fat grafting volume retention change from baseline to 12-months.

Patient Satisfaction1 Year

Sientra Breast Satisfaction Questionnaire survey results at 1, 3, 6 and 12-months post-operatively compared to baseline, based on a rating scale between 1 ("Strongly Disagree") to 7 ("Strongly Agree").

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (14)

Meridian Plastic Surgery

🇺🇸

Carmel, Indiana, United States

Ascentist Plastic Surgery

🇺🇸

Overland Park, Kansas, United States

Tessler Plastic Surgery

🇺🇸

Scottsdale, Arizona, United States

Aura Aesthetica, Inc.

🇺🇸

Beverly Hills, California, United States

Baptist Miami / Miami Cancer Institute

🇺🇸

Miami, Florida, United States

NYU Langone Plastic Surgery Associates

🇺🇸

New York, New York, United States

Dallas Plastic Surgery

🇺🇸

University Park, Texas, United States

V Plastic Surgery

🇺🇸

West Long Branch, New Jersey, United States

Calo Aesthetics

🇺🇸

Louisville, Kentucky, United States

Luxurgery

🇺🇸

New York, New York, United States

Restora Austin

🇺🇸

Austin, Texas, United States

Hunstad Kortesis Bharti Cosmetic Surgery

🇺🇸

Huntersville, North Carolina, United States

Regional Plastic Surgery

🇺🇸

Richardson, Texas, United States

Bellevue Plastic Surgery

🇺🇸

Bellevue, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath